The rest of this year’s list is consistent with the previous year’s ranks, which is both a sign of the stability among biopharmas and a sign of the difficulty in commercializing new biologics without a major partner.
Several of the Top 10 are legit takeover targets, but no buyout deal is likely to close before the end of the year, so the biggest opportunity for a change is between the 7 and 8 spots, if Genzyme’s production woes cause enough of a revenue drop to allow CSL to slip by.
10th anniversary note: in our first edition, Amgen was tops with biopharma revenues of $3.2 billion. There are now eight companies with revenues higher than that!
—Gil Y. Roth, Editor
Top 10 Biopharmaceutical Companies | ||
01 | Roche/Genentech | $36,017 |
02 | Amgen | $14,642 |
03 | Novo Nordisk | $9,566 |
04 | Merck Serono | $7,454 |
05 | Baxter BioScience | $5,573 |
06 | Biogen Idec | $4,247 |
07 | Genzyme | $3,562 |
08 | CSL Ltd.* | $3,211 |
09 | Allergan | $1,310 |
10 | Alexion Pharma | $387 |
Based on 2009 biopharma revenues.*
Note: In all Top Company profiles, dollar amounts are in millions.
* CSL's financial year ran from July 1, 2008 to June 30, 2009
Contributors
Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
All profiles written by Gil Roth, except Baxter Bioscience by Kristin Brooks
The Lowe Down capsules written by Derek Lowe
All pipeline information compiled by Kristin Brooks